Earnings Call · Q1 FY2025·2025-05-06

Q1 25EPS +16.84%·Rev n/aQ4 24EPS +8.73%·Rev n/aQ3 24EPS +29.59%·Rev n/aQ2 24EPS +19.74%·Rev n/a⚠ consensus missing

HALOZYME THERAPEUTICS, INC. HALO

Tram Bui — Investor Relations or Communications

Helen Torley — Chief Executive Officer

Nicole LaBrosse — Chief Financial Officer

+18.1%1d on move date+17.7% vs SPY3d+10.9%5d−15.4%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more HALO calls or request research access.

More HALO calls Browse calls Request research access